Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer.

It has headquarters in Philadelphia and Milton Park.

[1] In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer.

Tecelra is the first T cell therapy to be approved for use against a solid tumor.

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub.